Variability in commercial carbamazepine samples - Impact on drug release

International Journal of Pharmaceutics

Volumn 410, Issue 1-2, 2011, Pages 99-106

  Flicker, Felicia ^a   Eberle, Veronika Anna ^a   Betz, Gabriele ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Carbamazepine; Dihydrate; Morphology; Polymorphism; Preformulation; Tablet filler

Indexed keywords

CARBAMAZEPINE; FILLER; MANNITOL; MICROCRYSTALLINE CELLULOSE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISK INTRINSIC DISSOLUTION RATE; DRUG PURITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

ANTICONVULSANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CELLULOSE; CRYSTALLIZATION; EXCIPIENTS; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; SOLUBILITY; TABLETS; X-RAY DIFFRACTION;

EID: 79955627408     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.03.032     Document Type: Article

References (43)

1. Al-Zein, H., Riad, L.E., Abd-Elbary, A., 1999. Effect of packaging and storage on the stability of carbamazepine tablets. Drug Dev. Ind. Pharm. 25, 223-227.
2. Blagden, N., de Matas, M., Gavan, P.T., York, P., 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59, 617-630.
3. Bolourtchian, N., Nokhodchi, A., Dinarvand, R., 2001. The effect of solvent and crystallization conditions on habit modification of carbamazepine. Daru 9, 12-22. (Pubitemid 33806654)
4. Brittain, H.G., 2004. Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phase. J. Pharm. Sci. 93, 375-383.
5. Davidson, A., 1995. A multinational survey of the quatity of carbamazepine tablets. Drug Dev. Ind. Pharm. 21, 2167-2186.
6. FDA, 1997. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Center for Drug Evaluation and Research, Rockville, MD, August.
7. Fleischman, S.G., Kuduva, S.S., McMahon, J.A., Moulton, B., Walsh, R.D.B., Rodrìguez-Hornedo, N., Zaworotko, M.J., 2003. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids invloving carbamazepine. Cryst. Growth Des. 3, 909-919.
8. Getsoian, A., Lodaya, R., Blackburn, A., 2008. One-solvent polymorph screen of carbamazepine. Int. J. Pharm. 348, 3-9.
9. Gift, A.D., Luner, P.E., Luedeman, L., Taylor, L.S., 2008. Influence of polymeric excipients on crystal hydrate formation kinetics in aqueous slurries. J. Pharm. Sci. 97, 5198-5211.
10. Grzesiak, A.L., Lang, M., Kim, K., Matzger, A.J., 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J. Pharm. Sci. 92, 2260-2271.
11. Hanson, R., Gray, V., 2004. Dissolution testing of solid dosage forms. In: Handbook of Dissolution Testing, 3rd ed. Dissolution Technologies, Inc., Hockessin, Delaware, pp. 33-71.
12. Joshi, B.V., Patil, V.B., Pokharkar, V.B., 2002. Compatibility studies between carbamazepine and tablet excipients using thermal and non-thermal methods. Drug Dev. Ind. Pharm. 28, 687-694.
13. Kipouros, K., Kachrimanis, K., Nikolakakis, I., Malamataris, S., 2005. Quantitative analysis of less soluble form IV in commercial carbamazepine (form III) by diffuse reflectance Fourier transform spectroscopy (DRIFTS) and lazy learning algorithm. Anal. Chim. Acta 550, 191-198.
14. Kobayashi, Y., Ito, S., Itai, S., Yamamoto, K., 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193, 137-146.
15. Krahn, F.U., Mielck, J.B., 1987. Relation between several polymorphic forms and the dihydrate of carbamazepine. Pharm. Acta Helv. 62, 247-254.
16. Krahn, F.U., Mielck, J.B., 1989. Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine. Int. J. Pharm. 53, 25-34.
17. Laine, E., Tuominen, V., Ilvessalo, P., Kahela, P., 1984. Formation of dihydrate from carbamazepine anhydrate in aqueous conditions. Int. J. Pharm. 20, 307-314.
18. Lake, O.A., Olling, M., Barends, D.M., 1999. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur. J. Pharm. Biopharm. 48, 13-19.
19. Lefebvre, C., Guyot-Hermann, A.M., Draguet-Brughmans, M., Bouch, R., Guyot, J.C., 1986. Polymorphic transitions of carbamazepine during grinding and compression. Drug Dev. Ind. Pharm. 12, 1913-1927.
20. Lehto, P., Aaltonen, J., Tenho, M., Rantanen, J., Hirvonen, J., Tanninen, V.P., Peltonen, L., 2008. Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J. Pharm. Sci. 98, 985-996.
21. Li, Y., Chow, P.S., Tan, R.B.H., Black, S.N., 2008. Effect of water activity on the transformation between hydrate and anhydrate of carbamazepine. Org. Process Res. Dev. 12, 264-270.
22. Lindenberg, M., Kopp, S., Dressman, J.B., 2004. Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58, 265-278.
23. Mahalaxmi, R., Ravikumar, Pandey, S., Shirwaikar, A., Shirwaikar, A., 2009. Effect of recrystallization on size, shape, polymorph and dissolution of carbamazepine. Int. J. PharmTech Res. 1, 725-732.
24. McGregor, C., Saunders, M.H., Buckton, G., Saklatvala, R.D., 2004. The use of high-speed differential scanning calorimetry (hyper-DSC) to study the thermal properties of carbamazepine polymorphs. Thermochim. Acta 417, 231-237.
25. McMahon, L.E., Timmins, P., Williams, A.C., York, P., 1996. Characterization of dihydrates prepared from carbamazepine polymorphs. J. Pharm. Sci. 85, 1064-1069.
26. Meyer, M.C., Staughn, A.B., Mhatre, R.M., Shah, V.P., Williams, R.L., Lesko, L.J., 1998. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm. Res. 15, 1787-1791.
27. Meyer, M.C., Straughn, A.B., Jarvi, E.J., Wood, G.C., Pelsor, F.R., Shah, V.P., 1992. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 9, 1612-1616.
28. Mittapalli, P.K., Suresh, B., Hussaini, S.S.Q., Rao, Y.M., Apte, S., 2008. Comparative in vitro study of six carbamazepine products. AAPS PharmSciTech 9, 357.
29. Mosharraf, M., Sebhatu, T., Nyström, C., 1999. The effects of disordered structure on the solubility and dissolution rates of some hydrophilic, sparingly soluble drugs. Int. J. Pharm. 177, 29-51.
30. Murphy, D., Rodrguez-Cintrón, F., Langevin, B., Kelly, R.C., Rodrguez-Hornedo, N., 2002. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J. Pharm. 246, 121-134.
31. Otsuka, M., Ohfusa, T., Matsuda, Y., 2000. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Colloids Surface 17, 145-152.
32. Qiu, Y., Chen, Y., Liu, L., Zhang, G.G.Z. (Eds.), 2009. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice, Solvates/Hydrates. Academic Press, pp. 32-34 (Chapter 2.3.2).
33. Qu, H., Louhi-Kultanen, M., Kallas, J., 2006. Solubility and stability of anhydrate/hydrate in solvent mixtures. Int. J. Pharm. 321, 101-107.
34. Rodrìguez-Hornedo, N., Murphy, D., 2004. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci. 93, 449-460.
35. Salameh, A.K., Taylor, L.S., 2006. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J. Pharm. Sci. 95, 446-461.
36. 2O) in a mixture by powder X-ray diffractometry. Pharm. Res. 6, 1017-1024.
37. Tian, F., Sandler, N., Gordon, K.C., McGoverin, C.M., Reay, A., Strachan, C.J., Saville, D.J., Rades, T., 2006a. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: a single crystal study using sem and raman microscopy. Eur. J. Pharm. Biopharm. 64, 326-335.
38. Tian, F., Zeitler, J., Strachan, C., Saville, D., Gordon, K., Rades, T., 2006b. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using raman spectroscopy. J. Pharm. Biomed. Anal. 40, 271-280.
39. Šehić, S., Betz, G., Š Hadžidedić, El-Arini, S.K., Leuenberger, H., 2010. Investigation of intrinsic dissolution behavior of different carbamazepine samples. Int. J. Pharm. 386, 77-90.
40. Wrolstad, R.E., Decker, E.A., Schwartz, S.J., Sporns, P., 2005. Measurement of water activity using isopiestic method. In: Handbook of Food Analytical Chemistry, Water, Proteins, Enzymes, Lipids, and Carbohydrates. Wiley-IEEE, p. 51 (Chapter A2.3).
41. Yu, L.X., Carlin, A.S., Amidon, G.L., Hussain, A.S., 2004. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 270, 221-227.
42. Zakeri-Milani, P., Barzegar-Jalali, M., Azimi, M., Valizadeha, H., 2009. Biopharmaceutical classification of drugs using intrinsic dissolution rate (idr) and rat intestinal permeability. Eur. J. Pharm. Biopharm. 73, 102-106.
43. Zeitler, J.A., Taday, P.F., Gordon, K.C., Pepper, M., Rades, T., 2007. Solid-state transition mechanism in carbamazepine polymorphs by time-resolved terahertz spectroscopy. ChemPhysChem 8, 1924-1927.